Stem cell research and therapy have reached a pivotal moment characterized by significant regulatory approvals and scientific breakthroughs, sharply contrasted by a persistent market of unproven, predatory interventions.

Approved Therapies and Scientific Advances

As of early 2026, the FDA and other global regulators have approved several cell-based gene therapies. Notable recent approvals include Ryoncil (remestemcel-L), approved in December 2024 for pediatric steroid-refractory acute graft-versus-host disease, and Casgevy and Lyfgenia for sickle cell disease. Hematopoietic stem cell (HSC) transplantation remains the most established stem cell therapy, used for decades to treat blood and immune disorders.

In the research pipeline, induced pluripotent stem cells (iPSCs)—adult cells reprogrammed to an embryonic-like state—are show ...